Stephan Grabbe
Stephan Grabbe is an expert in Dermatology at University Medical Center of the Johannes Gutenberg University Mainz (Germany). As of October 2026, ScienceLeadR ranks Stephan Grabbe in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Stephan Grabbe has authored 454 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 3 of them ongoing. SLR score: 1,411 (community average: 125). How the SLR is computed.
LeadR Profile
Dermatology
Subspecialties: Oncology - Immunology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 454
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Impact of immunocompromised status on real-world outcomes with avelumab treatment in advanced Merkel cell carcinoma: findings from the prospective MCC-TRIM registry. PMID 42855830 — registries, cells, merkel cells, therapeutics, carcinoma, merkel cell | Br J Dermatol | 2026 | 0 |
| KDM6B inhibition modulates monocyte activation and alleviates IMQ-induced psoriasis-like skin inflammation. PMID 42732058 — skin, cells, genes, t-lymphocytes, regulatory, monocytes, promoter regions, genetic, histones, cell communication, therapeutics, psoriasis | Cell Commun Signal | 2026 | 0 |
| Collagen turnover biomarkers as diagnostic, prognostic, and therapy monitoring indicators in gastric cancer. PMID 42627091 — translational research, biomedical, neoplasms, collagen, drug therapy, gastrointestinal neoplasms, biomarkers, therapeutics, stomach neoplasms, pharmacokinetics, chemotherapy | Cancer Biomark | 2026 | 1 |
| An analysis of acceptance, socioeconomic factors, and outcome of skin cancer screening among the cohort of the Gutenberg Health Study. PMID 42581668 — skin, neoplasms, skin diseases, history, socioeconomic factors, skin neoplasms | J Dtsch Dermatol Ges | 2026 | 0 |
| Anthralin-From Psoriasis Drug to Power Adjuvant. PMID 42506667 — skin, cells, imiquimod, immunization, vaccines, pharmaceutical preparations, anthralin, neoplasms, vaccination, therapeutics, psoriasis | Vaccines (Basel) | 2026 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| DICIT Efficacy of diclofenac added to an approved ongoing PD 1 inhibitor therapy that achieved stable disease as best response in metastatic melanoma patients A single arm phase II trial 2023-504191-26-00 — melanoma, diclofenac, therapeutics | Phase 2/Phase 3 | Recruiting | 2024 |
| A clinical study to test if an investigational treatment called BNT326 is safe and potentially beneficial when used alone or in combination with other investigational treatments such as BNT327 for people with advanced malignant tumors 2024-517261-16-00 — therapies, investigational, safety, neoplasms, immunotherapy, therapeutics, pharmacokinetics | Phase 1/Phase 2 | Recruiting | 2025 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First Line Therapy in Patients With Advanced Melanoma NCT06697301 — toll-like receptors, safety, melanoma, neoplasms, neoplasm metastasis, therapeutics, toll-like receptor 7 | Phase 2/Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map